A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

NCT04674956 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

401

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer Stage IV
Pancreatic Cancer Metastatic

Interventions

DRUG: Camrelizumab
DRUG: Paclitaxel(Albumin Bound) and Gemcitabine
DRUG: Placebo

Sponsor

RenJi Hospital